A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial (NCT02320435)
A Single-Arm Open-Label Multi-Centre Extension Study of Pertuzumab Administered As a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Study
🩺 Plain-English Summary (8th-Grade Level)
This is a single-arm, multi-center, open-label extension study designed to provide continued pertuzumab therapy to patients receiving pertuzumab as an investigational medicinal product (IMP) in a Roche-sponsored global study and who continue to receive pertuzumab at the end of the Parent study, as well as to collect long-term safety and efficacy data of pertuzumab therapy. Patients with solid tumors who have not experienced progressive disease in the Parent study and, in the investigator's opinion, may potentially benefit from continued pertuzumab treatment, will continue to receive pertuzumab until disease progression, unacceptable toxicity, investigator/patient decision, patient non-compliance, patient death, patient request to withdraw, or study termination by the Sponsor, whichever occurs first.
Who can join: Review the eligibility criteria below.
Location: Santa Casa de Misericordia de Porto Alegre — Porto Alegre, Rio Grande do Sul
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (62 Sites)
Showing the first 25 of 62 sites.
- Santa Casa de Misericordia de Porto Alegre — Porto Alegre, Rio Grande do Sul
- Hospital Amaral Carvalho — Jaú, São Paulo
- Instituto do Cancer do Estado de Sao Paulo - ICESP — São Paulo, São Paulo
- Hospital Sírio-Libanês — São Paulo, São Paulo
- Hospital Perola Byington — São Paulo, São Paulo
- Núcleo de Pesquisa São Camilo — São Paulo, São Paulo
- Instituto de Oncologia de Sorocaba - CEPOS — Sorocaba, São Paulo
- Instituto Nacional de Cancer - INCa — Rio de Janeiro,
- Beijing Cancer Hospital — Beijing,
- The First Hospital of Jilin University — Changchun,
- West China Hospital, Sichuan University — Chengdu,
- Zhejiang Cancer Hospital — Hangzhou,
- Harbin Medical University Cancer Hospital — Harbin,
- Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University) — Nanjing,
- Fudan University Shanghai Cancer Center — Shanghai,
- Fudan University Shanghai Cancer Center — Shanghai,
- Liaoning cancer Hospital & Institute — Shenyang,
- Hospital Metropolitano (Sede Lindora-Santa Ana) — San José,
- Centre Georges Francois Leclerc — Dijon,
- Centre Henri Becquerel — Rouen,
- Clinique Armoricaine Radiologie — Saint-Brieuc,
- Centre Rene Huguenin — Saint-Cloud,
- Hämatologisch-Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus — Frankfurt am Main,
- Praxis für Interdisziplinäre Onkologie und Hämatologie GbR — Freiburg im Breisgau,
- Praxis für Ambulante Onkologie im Krankenhaus Jerusalem — Hamburg,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Solid Tumors
- Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors — Basking Ridge, New Jersey
- Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours — Edmonton, Alberta
- Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) — Santa Monica, California
- Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors — Los Angeles, California
- Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors — Phoenix, Arizona
Explore by condition: All Solid Tumors clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.